L. Giustini

C. Gridelli, S. Novello, S. Palazzo, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic Role of Thymidylate Synthase Polymorphisms in Gastric Cancer Patients Treated with Surgery and Adjuvant Chemotherapy

G. Watanabe, V. Catalano, K. Kawakami, 2005, Clinical Cancer Research.

A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin

M. Maltoni, D. Amadori, G. Luporini, 1999 .

Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy

Paolo Carlini, Antonio Mazzei, Francesco Campione, 1999, The Lancet.

Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer

V. Catalano, M. Magnani, F. Graziano, 2007, Clinical chemistry and laboratory medicine.

Natural interferon-beta and tamoxifen in hormone-resistant patients with advanced breast cancer.

L. Giustini, F. Trippa, G. Sica, 1995, Anticancer research.

Combination of beta-interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer.

L. Giustini, G. Sica, G. Rossi, 1992, Anticancer research.

A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer.

A. Piga, S. Cascinu, R. Cellerino, 1996, British Journal of Cancer.

The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan/cetuximab.

R. Berardi, A. Zaniboni, S. Cascinu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Insulin‐like growth factor 1 expression correlates with clinical outcome in K‐RAS wild type colorectal cancer patients treated with cetuximab and irinotecan

R. Berardi, A. Zaniboni, S. Cascinu, 2010, International journal of cancer.

Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.

E. Maccaroni, A. Zaniboni, S. Cascinu, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab

E. Maccaroni, S. Cascinu, C. Loretelli, 2012, Journal of Translational Medicine.

The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.

R. Berardi, A. Zaniboni, S. Cascinu, 2011, The oncologist.

Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.

V. Catalano, I. Floriani, G. Schiavon, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PP 22 Analysis of HER-3, insulin-growth factor-1 (IGF-1), nuclear factor k-B (NF-kB) and epidermal growth factor receptor (EGFR) gene copy number (GCN) in the prediction of clinical outcome for K-RAS wild type colorectal cancer patients receiving irinotecan–cetuximab

E. Maccaroni, S. Cascinu, E. Galizia, 2011 .

Triple-Negative Breast Cancer: Current State of the Art

L. Giustini, S. Crispino, A. Martignetti, 2010, Tumori.

Triple-Negative Breast Cancer: Current State of the Art

L. Giustini, S. Crispino, A. Martignetti, 2010 .

Paclitaxel and Mitoxantrone in Metastatic Breast Cancer: A Phase II Trial of the Italian Oncology Group for Cancer Research

F. di Costanzo, F. Mazzoni, L. Giustini, 2004, Cancer investigation.

KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study.

C. Braconi, R. Bracci, F. Bianchi, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

KIT and PDGFR a mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study

C. Braconi, R. Bracci, F. Bianchi, 2008 .

Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at‐risk Italian population

V. Torri, G. Watanabe, V. Catalano, 2006, International journal of cancer.

Differences in the Availability of New Anti-Cancer Drugs for Italian Patients Treated in Different Regions. Results of Analysis Conducted by the Italian Society of Medical Oncology (AIOM)

P. Tagliaferri, L. Crinò, G. Beretta, 2010, Tumori.

Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients

L. Giustini, Rosa R. Silva, E. Testa, 1997, Breast Cancer Research and Treatment.

Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer

V. Catalano, I. Floriani, B. Vincenzi, 2009, The Pharmacogenomics Journal.

Granisetron plus dexamethasone in moderately emetogenic chemotherapy: evaluation of activity during three consecutive courses of chemotherapy

L. Giustini, E. Menichetti, R. Silva, 1996, Supportive Care in Cancer.

A long-term clinical experience with Lonidamine.

B. Silvestrini, L. Giustini, R. Mattioli, 1984, Oncology.

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors

F. di Costanzo, L. Antonuzzo, M. Falconi, 2016, Cancer medicine.

Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer.

V. Catalano, D. Rossi, B. Vincenzi, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.

S. Barni, R. Labianca, D. Amadori, 2021, European journal of cancer.

A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases

V. Catalano, D. Rossi, G. Fiorentini, 2013, Gastric Cancer.

Mucinous histology in advanced colorectal cancer patients treated with first-line irinotecan-and/or oxaliplatin-based chemotherapy

V. Catalano, F. Graziano, F. Loupakis, 2008 .

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy

L. Livi, S. Pignata, L. Ciuffreda, 2018, PloS one.

Quality of life (QOL) assessment with EORTC QLQ-C30 in daily clinical practice

L. Giustini, D. Iacopini, F. Giorgi, 2005 .

Disparity in the “time to patient access” to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM)

P. Tagliaferri, G. Beretta, F. Puglisi, 2011 .

Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM).

P. Tagliaferri, G. Beretta, F. Puglisi, 2011, Tumori.